HIV drug resistance detected during low-level Viraemia is associated with subsequent virologic failure

AIDS

Volumn 28, Issue 8, 2014, Pages 1125-1134

  Swenson, Luke C ^a   Min, Jeong Eun ^a   Woods, Conan K ^a   Cai, Eric ^a   Li, Jonathan Z ^b   Montaner, Julio S G ^a   Harrigan, P Richard ^a   Gonzalez Serna, Alejandro ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; HIV drug resistance; Low level viraemia; Viral load; Virologic failure

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW LEVEL VIREMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIROLOGY;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 84927912939     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000203     Document Type: Article

References (47)

1. Cohen C. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials 2009; 10:116-124.
2. BC Centre for Excellence in HIV/AIDS Therapeutic Guidelines Committee. Therapeutic guidelines: Antiretroviral treatment (ARV) of adult HIV infection. Vancouver: British Columbia Centre for Excellence in HIV/AIDS; 2011. pp. 1-48.
3. European AIDS Clinical Society. European AIDS Clinical Society Guidelines: clinical management and treatment of HIV-infected adults in Europe. 2011. http://www.eacsociety.org/Guidelines.aspx [accessed January 2014].
4. EACS. European AIDS Clinical Society (EACS) Guidelines version 6.1. 2012.
5. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13: 1-85.
6. Harrigan PR, Côté HC. Clinical utility of testing human immunodeficiency virus for drug resistance. Clin Infect Dis 2000; 30 (Suppl 2):S117-S122.
7. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, et al. Persisting long-term benefit of genotypeguided treatment for HIV-infected patients failing HAART. The Viradapt Study:week 48follow-up. Antiviral Ther 2000; 5:65-70.
8. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93.
9. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000; 5:41-48.
10. Shafer RW, Dupnik K, Winters MA, Eshleman SH. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. Los Alamos, NM: HIV Seq Compend; 2001.
11. Monogram Biosciences. Features of GenoSure PRIme. GenoSure PRIme 2013; 1:1.
12. Stelzl E, Troppan KT, Winkler M, Korn K, Kessler HH. Optimized protocol for detection of HIV-1 drug mutations in patients with low viral load. J Virol Meth 2010; 168:152-154.
13. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79:9625-9634.
14. Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, et al. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 2011; 25:665-669.
15. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti A-M. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 2010; 201:1303-1307.
16. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7:437-441.
17. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-989.
18. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002; 16:2035-2041.
19. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817.
20. Lo Re V, Gasink L, Kostman JR, Leonard D, Gross R. Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs 2004; 18:436-442.
21. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-1969.
22. Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J, Moore RD, Gallant JE, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1030-1037.
23. Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A. Drug resistance at low viraemia in HIV-1- Infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-1044.
24. Swenson LC, Gonzalez-Serna A, Min JE, Woods CK, Montaner JSG, Li JZ, et al. HIV drug resistance occurring during low-level viremia is associated with subsequent virologic failure. Antiviral Ther 2013; 18:A1-A145.
25. Jordan MR, Winsett J, Tiro A, Bau V, Berbara RS, Rowley C, et al. HIV drug resistance profiles and clinical outcomes in patients with viremia maintained at very low levels. World J AIDS 2013; 03:71-78.
26. Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother 2012; 56:5998-6000.
27. Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima V, Montaner JSG, et al. Performance of HIV-1 drug resistance testing at low level viraemia and its ability to predict future virological outcomes in treatment-naïve individuals. Clin Infect Dis (in press) doi:10.1093/cid/ciu019.
28. Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012; 50:1936-1942.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.2013; 5:1-240.
30. Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: A recurrent events analysis. J Infect Dis 2012; 205:1230-1238.
31. Liu TF, Shafer RW. Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
32. Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 2008; 48:26-34.
33. Winters B, Van-Craenenbroeck E, Van-Der-Borght K, Lecocq P, Villacian J, Bacheler L. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Meth 2009; 162:101-108.
34. Swenson LC, Pollock G, Wynhoven B, Mo T, Dong W, Hogg RS, et al. Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice. PLoS One 2011; 6:e17402.
35. Laprise C, de-Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 2013; 57:1489-1496.
36. Charpentier C, Landman R, Laouenan C, Joly V, Hamet G, Damond F, et al. Virological outcome of patients displaying persistent low-level viremia comprised between 20 and 50 copies/ml [Abstract]. CROI; March 5-8, 2012; Seattle, WA. pp. 349.
37. Do T, Duncan J, Butcher A, Liegler T. Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds. J Clin Virol 2011; 52 Suppl 1:S83-S89.
38. Chao C, Tang B, Towner W, Silverberg MJ, Hurley L, Horberg M. Short-term clinical outcomes among treatmentexperienced HIV-positive patients with early low level viremia. AIDS Patient Care STDs 2012; 26:253-255.
39. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
40. Deeks SG. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA 2001; 286:224-226.
41. Gandhi RT, Deeks SG. Plasma HIV-1 RNA levels during antiretroviral therapy: How low is low enough? Clin Infect Dis 2012; 54:733-735.
42. Montaner JSG, Richman DD, Hammer SM. Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis 2009; 49:1283-1284.
43. Manavi K. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin Trials 2008; 9:283-286.
44. Lima VD, Gill VS, Yip B, Hogg RS, Montaner JSG, Harrigan PR. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 2008; 198:51-58.
45. Harrigan PR, Hogg RS, Dong WWY, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
46. Lima V, Harrigan R, Montaner JSG. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51:3-6.
47. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.